Tisagenlecleucel shows no EFS improvement on standard of care in 2L for aggressive B-cell NHL

Share :
Published: 14 Dec 2021
Views: 750
Dr Michael Bishop - University of Chicago, Chicago, USA

Dr Michael Bishop speaks to ecancer about the analysis of the phase III Belinda study.

This study investigates tisagenlecleucel vs standard of care as second-line therapy of primary refractory or relapsed aggressive B-cell non-Hodgkin lymphoma.

Initially, he talks about the background of the study. Dr Bishop then discusses the methods and results of this study. 

He says that tisa-cel as 2nd line treatment in R/R aNHL patients did not have a higher event-free survival vs standard of care. 

He concludes by saying that results from this randomised phase III study will inform use of cellular treatment in the 2L R/R aNHL setting and the design of future CAR-T trials.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.